French biotechnology firm Abivax has reported positive findings from the evaluation of the ability of its product candidate ABX464 to mitigate intestinal inflammation in HIV patients.

ABX464 is an antiviral small molecule designed to target RNA biogenesis by inhibiting the HIV REV protein in viral replication.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The results from a completed Phase IIa clinical trial indicated pharmacological reduction of HIV reservoir in peripheral blood mononuclear cells (PBMCs) with ABX464 in HIV patients.

ABX464 was found to decrease the inflammation by inducing Il-22 production in activated macrophages.

Based on these results, the firm intends to investigate potential use of the drug candidate for inflammatory bowel disease (IBD) treatment, with plans to commence another Phase IIa trial in ulcerative colitis patients in the coming months.

See Also:

"Based on these encouraging results, ABIVAX is initiating a Phase IIa proof-of-concept clinical study in patients with ulcerative colitis during the second half of 2017."

Abivax CEO professor Hartmut Ehrlich said: “We are pleased to see publication of our data, which gives us valuable insight into ABX464’s activity in HIV and also supports its potential role as a novel and differentiated treatment for inflammatory bowel disease and especially ulcerative colitis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Based on these encouraging results, ABIVAX is initiating a Phase IIa proof-of-concept clinical study in patients with ulcerative colitis during the second half of 2017.”

During preclinical studies, ABX464 triggered a long-lasting reduction of viral load and demonstrated protection against the lethal effects of dextran sulfate sodium (DSS) given for experimental colitis.

In addition to a decrease in production of the pro-inflammatory cytokines IL-6, TNFα and chemoattractant MCP-1 in colon, ABX464 was found to protect the intestine from changes caused by severe inflammation.